Related Experiment Video
Updated: May 8, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Use of enoxaparin in end-stage renal disease
1Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy. silvia.lai@uniroma1.it
Abstract:
Enoxaparin has become the treatment of choice for various thromboembolic diseases. In most patients with end-stage renal disease (ESRD), prophylactic dosage of enoxaparin does not appear to be associated with an increased bleeding risk and can be used without the need for monitoring and adjustment of regimens. Empirical dose adjustment and biological monitoring seem to be necessary along with therapeutic doses. Anti-factor Xa poorly predicts the degree of anticoagulation in ESRD patients given enoxaparin.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Chronic Kidney Disease III: Interprofessional Care
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
